FMP

FMP

Enter

AZRX - AzurRx BioPharma, In...

Financial Summary of AzurRx BioPharma, Inc.(AZRX), AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the tre

photo-url-https://financialmodelingprep.com/image-stock/AZRX.jpg

AzurRx BioPharma, Inc.

AZRX

NASDAQ

Inactive Equity

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

3.45 USD

0.06999993 (2.03%)

About

ceo

Mr. James Sapirstein

sector

Healthcare

industry

Biotechnology

website

http://www.azurrx.com

exchange

NASDAQ

Description

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine...

CIK

0001604191

ISIN

US05502L1052

CUSIP

05502L105

Address

760 Parkside Ave Ste 304

Phone

16466997855

Country

US

Employee

12

IPO Date

Oct 11, 2016

Summary

CIK

0001604191

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

05502L105

ISIN

US05502L1052

Country

US

Price

3.45

Beta

1.51

Volume Avg.

713.03k

Market Cap

3.43M

Shares

-

52-Week

3.38-3.66

DCF

3.56

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-1.84

P/B

-

Website

http://www.azurrx.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest AZRX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep